RxKinetix, Inc. And Indian Immunologicals Limited Collaborate On Development Of Thermostable Hepatitis B Vaccines
Published: Nov 02, 2005
LOUISVILLE, Colo., Nov. 2 /PRNewswire/ -- RxKinetix Inc., a specialty pharmaceutical company developing new therapeutics focused on un-met needs in oncology care, and Indian Immunologicals Ltd, a leading manufacturer of veterinary and human vaccines, today announced they will collaborate in the development of thermostable Hepatitis B vaccines with improved stability at non-refrigerated temperatures. This project is funded by a grant awarded to RxKinetix from the Foundation for the National Institutes of Health through the Grand Challenges in Global Health Initiative.
As part of the collaboration, Indian Immunologicals Limited will supply RxKinetix with Hepatitis B vaccine, which will be formulated by RxKinetix in its ProJuvant(TM) vaccine delivery platform and tested for thermostability. Formulations showing good potential will then be tested in vivo.
"Indian Immunologicals is an ideal collaborator for RxKinetix in this project," said Marazban Sarkari, Ph.D., Principal Investigator for the Grand Challenges Grant. "They are aggressively pursuing a strategy that would increase vaccinations to improve health in India and other Asian countries and so they have a great interest in seeing this project succeed."
"We are very pleased to be working with RxKinetix," said Dr. V. A. Srinivasan, Research Director, Indian Immunologicals Limited. "Their ProJuvant technology has shown real promise in improving the efficacy of certain vaccines. The additional demonstration of thermostability will mean these vaccines could potentially be of great value, especially in tropical countries."
RxKinetix, Inc. is a specialty pharmaceutical company developing new therapeutics focused in oncology care. Using proven pharmaceuticals and proprietary polymer-based drug delivery technologies, RxKinetix creates new drugs or enhances existing drugs. The Company's strategy improves timelines and reduces risk during clinical development. RxKinetix has a strong intellectual property portfolio in support of its products and technologies. More information regarding RxKinetix is available at www.rxkinetix.com.
About Indian Immunologicals
Indian Immunologicals Limited (IIL) is a wholly owned subsidiary of the National Dairy Development Board and was set up in 1983 to manufacture Foot and Mouth Disease (FMD) vaccine in India. IIL is the fifth largest player in the animal health market in India and the market leader in veterinary vaccines. Human Biologicals Institute (HBI), a division of Indian Immunologicals Limited, manufactures purified Vero cell rabies vaccine (PVRV) marketed under the brand name 'Abhayrab' and is shortly planning to launch a range of pediatric vaccines, including hepatitis B and combinations. More information regarding Indian Immunologicals is available at www.indimmune.com.RxKinetix Inc.
CONTACT: Joanna K. Money, Ph.D., VP, Corporate Development of RxKinetix,+1-303-926-1900, or Email, email@example.com